REGINfo: NOVARTIS - Chimie de spécialité - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
- Remgro
- RICHEMONT
- RMB Holdings
- Sanlam
- Sasol
- Shoprite
- Standard Bank Group
- Tiger Brands
- Vodacom Group
- WOOLWORTHS
> TA 25
Israel - TA 25
- AVNER OIL
- AZRIELI GROUP
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- GAZIT GLOBE
- ICL
- IFF
- ISRAEL CORP
- KENON
- LEUMI
- MIGDAL INSURANCE
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- OSEM
- PAZ OIL
- PERRIGO
- POALIM
- STRAUSS GROUP
- TEVA

Europe

COMPANY SEARCH RESULT

$NOVARTIS: Click to view the issuer\'s details$

Last update : 28/01/2011 >View issuer details

2020.02.28 | 13:00 | Permanent Information Releases / General Company News

puce Die Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrates gut - HTML (w)

2020.02.28 | 13:00 | Permanent Information Releases / General Company News

puce Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting - HTML (w)

2020.02.28 | 13:00 | Permanent Information Releases / General Company News

puce Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration à l’Assemblée générale annuelle - HTML (w)

2020.02.24 | 07:15 | Permanent Information Releases / General Company News

puce Novartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS) - HTML (w)

2020.02.17 | 12:11 | Permanent Information Releases / General Company News

puce Novartis receives EC Approval for Beovu®, a next-generation anti-VEGF treatment for wet AMD, a leading cause of blindness worldwide - HTML (w)

2020.02.11 | 07:15 | Permanent Information Releases / General Company News

puce Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review - HTML (w)

2020.01.31 | 07:30 | Permanent Information Releases / General Company News

puce Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicines - HTML (w)

2020.01.29 | 07:00 | Permanent Information Releases / Sales and Revenues

puce Novartis erzielt 2019 ein starkes Umsatzwachstum, Margen-steigerungen und bahnbrechende Innovationen mit der Markt¬einführung fünf neuer Wirkstoffe - HTML (w)

2020.01.29 | 07:00 | Permanent Information Releases / Sales and Revenues

puce Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019 - HTML (w)

2020.01.29 | 07:00 | Permanent Information Releases / Sales and Revenues

puce Novartis a réalisé en 2019 une forte croissance de son chiffre d’affaires, une augmentation de sa marge et une percée dans l’innovation en lançant cinq nouvelles entités moléculaires - HTML (w)

2020.01.20 | 15:32 | Permanent Information Releases / General Company News

puce Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease - HTML (w)

2020.01.16 | 09:00 | Permanent Information Releases / General Company News

puce Public-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million People - HTML (w)

2020.01.06 | 18:05 | Permanent Information Releases / General Company News

puce Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran - HTML (w)

2020.01.06 | 07:00 | Public offerings / Statement of purchases / sales

puce Novartis completes tender offer for all outstanding shares of The Medicines Company - HTML (w)

2019.12.16 | 07:15 | Permanent Information Releases / General Company News

puce Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1284